SCHEMBL3576476

SCHEMBL3576476

CN(C)CCCCNc1c(C#N)cnc2oc(-c3ccccc3)c(-c3ccccc3)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.58
RAD52 P43351 3/20 0.58
MEN1 O00255 2/20 0.53
POLB P06746 2/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
HSD17B10 Q99714 4/20 0.44
GAA P10253 1/20 0.44
CHEK1 O14757 3/20 0.41
AURKA O14965 3/20 0.41
MAP2K1 Q02750 1/20 0.41
TNK2 Q07912 7/20 0.40
LCK P06239 3/20 0.40
NPC1 O15118 1/20 0.39
SLC2A1 P11166 1/20 0.39
APOBEC3A P31941 1/20 0.39
RAB9A P51151 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
USP2 O75604 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563328 0.86 AURKA (0.51) KMT2ARAD52MEN1POLBKDM4E
SCHEMBL3579856 0.83 CHEK1 (0.47) KMT2ARAD52MEN1KDM4EALDH1A1
SCHEMBL3564842 0.79 AURKA (0.48) CHEK1AURKAMAP2K1TNK2LCK
SCHEMBL3562107 0.79 AURKA (0.62) KMT2ARAD52MEN1POLBKDM4E
SCHEMBL3566479 0.78 KDM4E (0.53) KDM4EALDH1A1HPGDHSD17B10AURKA
SCHEMBL3568195 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10AURKA
SCHEMBL3566242 0.78 CHEK1 (0.44) KMT2ARAD52MEN1CHEK1AURKA
SCHEMBL3572103 0.78 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10AURKA
SCHEMBL3568846 0.78 TNK2 (0.50) KMT2AMEN1CHEK1AURKAMAP2K1
SCHEMBL3566457 0.77 LRRK2 (0.49) KMT2ARAD52MEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 KMT2A 4192/4885RAD52 3125/4885MEN1 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.